A Phase 1, 2-Part, Open-label Study to Evaluate Relative Bioavailability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants (Part 1), and a Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986460 in Healthy Adult Male Participants (Part 2)
Latest Information Update: 09 Oct 2025
At a glance
- Drugs BMS 986460 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 19 Sep 2025 Planned End Date changed from 29 Aug 2025 to 29 Oct 2025.
- 19 Sep 2025 Planned primary completion date changed from 29 Aug 2025 to 29 Oct 2025.
- 13 Apr 2025 Status changed from not yet recruiting to recruiting.